Algernon Health

Algernon Health (formerly Algernon Pharmaceuticals) is a Canadian clinical-stage healthcare company that has strategically pivoted toward the Alzheimer's disease diagnostic market while maintaining a robust drug repurposing pipeline. The company is establishing a network of specialized neuroimaging clinics across North America equipped with FDA-cleared, brain-specific PET scanning technology to detect amyloid plaques with lower radiation exposure. Through its subsidiary, Algernon NeuroScience, the company is advancing a proprietary form of N,N-Dimethyltryptamine (DMT) for the treatment of stroke and traumatic brain injury, currently in Phase 2 development. Additionally, Algernon is investigating Repirinast for chronic kidney disease and retains a significant equity stake in the chronic cough program acquired by Seyltx. The company's business model focuses on capital-efficient drug development and the provision of high-demand diagnostic services for neurodegenerative disorders.